These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34412521)

  • 1. Can treatment response to SGLT2-inhibitors in syndrome of inappropriate antidiuresis be predicted by copeptin, natriuretic peptides and inflammatory markers?
    Nobbenhuis R; Refardt J; Vogt D; Sailer CO; Winzeler B; Christ-Crain M
    Biomarkers; 2021 Nov; 26(7):647-655. PubMed ID: 34412521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.
    Refardt J; Imber C; Sailer CO; Jeanloz N; Potasso L; Kutz A; Widmer A; Urwyler SA; Ebrahimi F; Vogt DR; Winzeler B; Christ-Crain M
    J Am Soc Nephrol; 2020 Mar; 31(3):615-624. PubMed ID: 32019783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
    Refardt J; Imber C; Nobbenhuis R; Sailer CO; Haslbauer A; Monnerat S; Bathelt C; Vogt DR; Berres M; Winzeler B; Bridenbaugh SA; Christ-Crain M
    J Am Soc Nephrol; 2023 Feb; 34(2):322-332. PubMed ID: 36396331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of nonresponse to fluid restriction in hyponatraemia due to the syndrome of inappropriate antidiuresis.
    Winzeler B; Lengsfeld S; Nigro N; Suter-Widmer I; Schütz P; Arici B; Bally M; Blum C; Bock A; Huber A; Müller B; Christ-Crain M
    J Intern Med; 2016 Dec; 280(6):609-617. PubMed ID: 27481546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
    Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
    Cardiovasc Diabetol; 2021 Jun; 20(1):105. PubMed ID: 34183012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
    Nassif ME; Qintar M; Windsor SL; Jermyn R; Shavelle DM; Tang F; Lamba S; Bhatt K; Brush J; Civitello A; Gordon R; Jonsson O; Lampert B; Pelzel J; Kosiborod MN
    Circulation; 2021 Apr; 143(17):1673-1686. PubMed ID: 33550815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
    Bosch A; Ott C; Jung S; Striepe K; Karg MV; Kannenkeril D; Dienemann T; Schmieder RE
    Cardiovasc Diabetol; 2019 Mar; 18(1):44. PubMed ID: 30922297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Furosemide, Oral Sodium Chloride, and Fluid Restriction for Treatment of Syndrome of Inappropriate Antidiuresis (SIAD): An Open-label Randomized Controlled Study (The EFFUSE-FLUID Trial).
    Krisanapan P; Vongsanim S; Pin-On P; Ruengorn C; Noppakun K
    Am J Kidney Dis; 2020 Aug; 76(2):203-212. PubMed ID: 32199708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
    Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
    Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresis.
    Fenske WK; Christ-Crain M; Hörning A; Simet J; Szinnai G; Fassnacht M; Rutishauser J; Bichet DG; Störk S; Allolio B
    J Am Soc Nephrol; 2014 Oct; 25(10):2376-83. PubMed ID: 24722436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copeptin in the differential diagnosis of hyponatremia.
    Fenske W; Störk S; Blechschmidt A; Maier SG; Morgenthaler NG; Allolio B
    J Clin Endocrinol Metab; 2009 Jan; 94(1):123-9. PubMed ID: 18984663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
    Kinduryte Schorling O; Clark D; Zwiener I; Kaspers S; Lee J; Iliev H
    Adv Ther; 2020 Aug; 37(8):3463-3484. PubMed ID: 32372290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of empagliflozin for syndrome of inappropriate antidiuresis.
    Carney EF
    Nat Rev Nephrol; 2023 Feb; 19(2):73. PubMed ID: 36513846
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
    Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Abe M; Nakamura J; Yamamoto K; Kayama K; Kawahira M; Tanabe K; Fujikawa K; Hata M; Fujita Y; Umayahara Y; Taniuchi S; Sanada S; Shintani A; Fukunami M
    Circ Heart Fail; 2021 Mar; 14(3):e007048. PubMed ID: 33663235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.
    Januzzi JL; Zannad F; Anker SD; Butler J; Filippatos G; Pocock SJ; Ferreira JP; Sattar N; Verma S; Vedin O; Schnee J; Iwata T; Cotton D; Packer M;
    J Am Coll Cardiol; 2021 Sep; 78(13):1321-1332. PubMed ID: 34556318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
    Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
    Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
    Damman K; Beusekamp JC; Boorsma EM; Swart HP; Smilde TDJ; Elvan A; van Eck JWM; Heerspink HJL; Voors AA
    Eur J Heart Fail; 2020 Apr; 22(4):713-722. PubMed ID: 31912605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
    Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of hyponatremia normalization on osteoblast function in patients with SIAD.
    Potasso L; Refardt J; Meier C; Christ-Crain M
    Eur J Endocrinol; 2021 Nov; 186(1):1-8. PubMed ID: 34678762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.